As the CEO and Founder of Corstasis Therapeutics, Benjamin Esque is at the forefront of innovation in the clinical stage pharmaceutical sector, particularly focusing on novel diuretic therapies. With a robust background in pharmaceuticals and cardiovascular medical devices, Benjamin has successfully spearheaded the development of...
As the CEO and Founder of Corstasis Therapeutics, Benjamin Esque is at the forefront of innovation in the clinical stage pharmaceutical sector, particularly focusing on novel diuretic therapies. With a robust background in pharmaceuticals and cardiovascular medical devices, Benjamin has successfully spearheaded the development of a pipeline aimed at providing outpatient therapeutic options for patients grappling with fluid overload. His leadership is characterized by a strategic vision that integrates extensive experience in startup formation, capital raising, and product development, ensuring that Corstasis Therapeutics remains agile and responsive to market needs.
Under Benjamin's guidance, the company is advancing its lead product—a groundbreaking formulation of a potent diuretic designed to bypass first-pass metabolism. This innovative approach not only enhances the efficacy of the treatment but also aims to improve patient outcomes by preventing further complications associated with fluid overload. Benjamin's expertise in navigating complex FDA processes, particularly in the realm of 505(b)(2) pharmaceuticals and 510(k) medical devices, has been instrumental in driving the company's regulatory strategy and ensuring timely market entry.
His skills in business analysis, market development, and sales management are pivotal as Corstasis Therapeutics positions itself within a competitive landscape. By fostering strong relationships and engaging in effective contract negotiation, Benjamin is committed to building a sustainable business model that prioritizes patient care while delivering value to stakeholders. With a focus on innovation and a deep understanding of the healthcare ecosystem, Benjamin Esque is not just leading a company; he is shaping the future of therapeutic options in the pharmaceutical industry.
